Market Overview:
The global tenofovir/lamivudine/atazanavir/ritonavir combination drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of HIV and rising demand for combination drugs. In addition, the growing awareness about HIV and its treatment is also contributing to the growth of this market. On the basis of type, the global tenofovir/lamivudine/atazanavir/ritonavir combination drug market can be segmented into 10 tables and 30 tables. The 10 tables segment is expected to account for a major share of this market during the forecast period owing to its lower price point as compared with 30 tables. On the basis of application, this market can be divided into hospital, clinic, drug center, and other segments. The hospital segment is anticipated to hold a leading position in terms of revenue contribution during 2018-2030 owing to an increase in number of patients suffering from HIV across different geographies.
Product Definition:
Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug is a medication used to treat HIV. It is a combination of tenofovir, lamivudine, atazanavir, and ritonavir. This drug helps to reduce the amount of HIV in the body and can help to slow down or stop the progression of AIDS.
10 Tables:
10 tables is a combination drug that contains tenofovir, lamivudine, atazanavir and ritonavir. It was approved by the FDA in June 2007 as the first drug containing atazanovir with any type of antiretroviral. 10 tables has been found to be effective against HIV-1 infection in clinical trials and is expected to become an essential medicine for people living with HIV/AIDS over the coming years.
30 Tables:
30 tables is the maximum number of drugs that can be combined in a single tablet. It includes tenofovir/lamivudine/atazanavir/ritonavir combination and tenofovir disoproxil fumarate (ViroMed). The product was approved by the FDA in June 2014 for treatment of HIV-1 infection.
Application Insights:
In terms of revenue, the other application segment dominated the global tenofovir/lamivudine/atazanavir/ritonavir combination drug market with a share of 29.1% in 2017. This is attributed to the high unmet medical needs of patients living with HIV and an increase in new infections worldwide. As per UNAIDS, there were around 37 million people living with HIV across the globe in 2017; out of which 19 million were receiving antiretroviral therapy (ART). Thus, a large patient base remains untreated due to financial constraints and geographical barriers preventing them from accessing quality healthcare services at affordable costs.
The hospital application segment is expected to witness lucrative growth over the forecast period owing to rising awareness programs conducted by public-private partnerships such as Merck AIDS Foundation's MAFRO program that provides free medication for more than one million people annually throughout Africa through its clinics and hospitals network.
Regional Analysis:
North America dominated the global tenofovir/lamivudine/atazanavir/ritonavir combination drug market in terms of revenue share in 2017. The region is expected to continue its dominance over the forecast period as well owing to factors such as favorable reimbursement policies, increasing prevalence of HIV and rising awareness about treatment options among patients. Moreover, increasing investments by manufacturers for development of novel drugs are also contributing towards market growth. For instance, Gilead Sciences invested USD X million for research on hepatitis C virus (HCV) replication complexed with tenofovir alafenamide during 2014-2016 period which resulted into development of FOCUS HCV Antiviral Drug Candidate (FOCUS-PDC).
Asia Pacific is anticipated to witness lucrative growth over the forecast period due to growing target population base along with rising incidence rate of HIV infection in this region.
Growth Factors:
- Increasing incidence of HIV/AIDS: The global prevalence of HIV is currently around 34 million people and it is estimated to grow to more than 45 million by 2020. This will create a large pool of patients who will require treatment, thereby driving the demand for Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug market.
- Rising awareness about HIV and its treatment: There has been a significant increase in the awareness about HIV in recent years, which is likely to drive the demand for Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug market over the forecast period.
- Technological advancements in drug delivery systems: The development of novel drug delivery systems such as oral films and nanoparticles has made it easier for patients to take these drugs, which is likely to boost the demand for Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug market in future.
- Growing number of clinical studies on new combination therapies: There has been an increasing number of clinical studies being conducted on new combination therapies involving Tenofovir, Lamivudine, Atazanvir and Ritonvir, which is expected to fuel the growth of this market over the forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Research Report
By Type
10 Tables, 30 Tables
By Application
Hospital, Clinic, Drug Center, Other
By Companies
Emcure Pharmaceuticals, Hetero Drugs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Report Segments:
The global Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug market is segmented on the basis of:
Types
10 Tables, 30 Tables
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drug Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Emcure Pharmaceuticals
- Hetero Drugs
Highlights of The Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 10 Tables
- 30 Tables
- By Application:
- Hospital
- Clinic
- Drug Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tenofovir/lamivudine/atazanavir/ritonavir is a combination drug used to treat HIV. It works by blocking the virus from multiplying in the body.
Some of the major companies in the tenofovir/lamivudine/atazanavir/ritonavir combination drug market are Emcure Pharmaceuticals, Hetero Drugs.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market - Supply Chain
4.5. Global Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Forecast
4.5.1. Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Absolute $ Opportunity
5. Global Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Type
5.3.1. 10 Tables
5.3.2. 30 Tables
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Drug Center
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Demand Share Forecast, 2019-2026
9. North America Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Drug Center
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Type
9.7.1. 10 Tables
9.7.2. 30 Tables
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Demand Share Forecast, 2019-2026
10. Latin America Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Drug Center
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Type
10.7.1. 10 Tables
10.7.2. 30 Tables
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Demand Share Forecast, 2019-2026
11. Europe Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Drug Center
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Type
11.7.1. 10 Tables
11.7.2. 30 Tables
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Demand Share, 2019-2026
12. Asia Pacific Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Drug Center
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Type
12.7.1. 10 Tables
12.7.2. 30 Tables
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Demand Share, 2019-2026
13. Middle East & Africa Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Drug Center
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market Size and Volume Forecast by Type
13.7.1. 10 Tables
13.7.2. 30 Tables
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market: Market Share Analysis
14.2. Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Distributors and Customers
14.3. Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Emcure Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Hetero Drugs
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. COMPANY3
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
